OnCo
ideasIdea

Two-day CAR-T manufacture paired with rapid release tests that regulators accept

CAR-T can now be made in a day or two, but the safety tests to release it still take two weeks. Faster tests would let patients be treated within days.

Non-expanded or minimally expanded CAR-T processes (Novartis T-Charge and rapcabtagene autoleucel, several academic protocols) produce a product in 24-48 hours, but release still waits for compendial 14-day sterility, mycoplasma and vector copy number assays. The proposal is a regulatory pathway for rapid release: validated rapid microbial methods (PCR- or growth-based, 24-72 hours), qPCR mycoplasma, flow-based potency surrogates, and 'release-then-confirm' with infusion permitted after rapid tests and compendial tests completed in parallel, as is already accepted for some cord blood and radiopharmaceutical products.

Hypothesis
Rapid release cuts vein-to-vein time for fast-manufactured CAR-T to under seven days and reduces the proportion of enrolled patients who die or progress before infusion by half, with no increase in infusion-related infections.
Rationale
Ten to twenty percent of patients referred for CAR-T never receive it, largely because of progression during the wait. Short manufacture also yields less differentiated, more persistent T cells. Rapid sterility methods are validated in blood banking and radiopharmacy where product shelf life forces the issue.
What would test it
Sponsor a regulator-endorsed validation study of rapid microbial methods against compendial methods on 500 CAR-T batches, then a prospective cohort using release-then-confirm with 30-day infection surveillance.
Maturity
early clinical
Who has to act
regulator
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks

Connected

3top

Pages like this

not linked directly; found by shared links

technologies

1
CAR-T cell therapy

companies

1
Novartis

bottlenecks

1
Manufacturing cost and time for living and radioactive medicines